When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
EPZM - Epizyme's tazemetostat shows positive action in mid-stage FL study
Epizyme Inc.
Results from an open-label Phase 2 clinical trial evaluating Epizyme's (NASDAQ:EPZM) tazemetostat in follicular lymphoma (FL) patients, with or without EZH2 activating mutations, showed a treatment benefit. The data were presented at ASH in Orlando.
More news on: Epizyme, Inc., Healthcare stocks news,